|Day Low/High||9.69 / 10.91|
|52 Wk Low/High||2.58 / 13.55|
Financing Led by New Enterprise Associates (NEA)
Welcomes Renowned Thought Leaders Dr. Malcolm Brenner, Dr. Helen Heslop, and Dr. Cliona Rooney
Live Audio Webcast Scheduled for May 17th at 8:00 a.m. CT
Transaction Adds Multi-Antigen Targeted Cell Therapy Platform to TapImmune's Peptide Vaccine Portfolio
Company to Provide Corporate and Clinical Overview on Thursday, April 5, 2018, 4:30pm ET
Phase 1 Demonstration of Safety and Long-Lasting Immune Responses in Ovarian and Breast Cancer
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart TM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola...
TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell ...
TapImmune, Inc. (the “Company”), (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a ...
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial...
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr.
TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update ...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.